Edesa Biotech (EDSA) Debt Ratio (2021 - 2022)
Edesa Biotech (EDSA) posted Debt Ratio of 0.0 for Q3 2022, up 16.54% sequentially from 0.0 in Q3 2021, and up 16.54% YoY from 0.0 in Q3 2021.
Edesa Biotech (EDSA) Debt Ratio (2021 - 2022) Analysis & Trends
Edesa Biotech has reported Debt Ratio for 2 years, with the latest figure at 0.0 in Q3 2022.
- Quarterly Debt Ratio rose 16.54% year-over-year to 0.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 0.0 (up 16.54% YoY) and the FY2022 annual result came in at 0.0, up 16.54% from the prior year.
- Debt Ratio advanced to 0.0 in Q3 2022 per EDSA's latest filing, from 0.0 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.0 in Q3 2022 and troughed at 0.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.47 |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 0.00 |
| Sep 30, 2021 | 0.00 |